These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
171 related items for PubMed ID: 23419380
41. Noninvasive urinary metabonomic diagnosis of human bladder cancer. Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, Chiong E, Chan EC. J Proteome Res; 2010 Jun 04; 9(6):2988-95. PubMed ID: 20337499 [Abstract] [Full Text] [Related]
42. Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach. Zhang A, Sun H, Han Y, Yuan Y, Wang P, Song G, Yuan X, Zhang M, Xie N, Wang X. Analyst; 2012 Sep 21; 137(18):4200-8. PubMed ID: 22852134 [Abstract] [Full Text] [Related]
43. Idiopathic portal hypertension: a case report. Ziarkiewicz-Wróblewska B, Górnicka B, Wróblewski T, Małkowski PM, Zurakowski J, Krawczyk M, Wasiutyński A. Med Sci Monit; 2004 Nov 21; 10(11):CS69-72. PubMed ID: 15507857 [Abstract] [Full Text] [Related]
44. Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Hirayama A, Nakashima E, Sugimoto M, Akiyama S, Sato W, Maruyama S, Matsuo S, Tomita M, Yuzawa Y, Soga T. Anal Bioanal Chem; 2012 Dec 21; 404(10):3101-9. PubMed ID: 23052862 [Abstract] [Full Text] [Related]
45. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, Mattivi F, Latiano A, Andriulli A, Vrhovsek U, Pazienza V. Oncotarget; 2016 Feb 02; 7(5):5815-29. PubMed ID: 26735340 [Abstract] [Full Text] [Related]
51. Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L. J Proteome Res; 2011 Dec 02; 10(12):5433-43. PubMed ID: 22007635 [Abstract] [Full Text] [Related]
53. Metabolomic biomarkers in women with polycystic ovary syndrome: a pilot study. Atiomo W, Daykin CA. Mol Hum Reprod; 2012 Nov 02; 18(11):546-53. PubMed ID: 22809877 [Abstract] [Full Text] [Related]
55. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, Bosch J, García-Pagán JC. Gut; 2011 Aug 02; 60(8):1133-8. PubMed ID: 21427197 [Abstract] [Full Text] [Related]
56. Biomarkers of primary dysmenorrhea and herbal formula intervention: an exploratory metabonomics study of blood plasma and urine. Liu P, Duan J, Wang P, Qian D, Guo J, Shang E, Su S, Tang Y, Tang Z. Mol Biosyst; 2013 Jan 27; 9(1):77-87. PubMed ID: 23111557 [Abstract] [Full Text] [Related]
57. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Liver Transpl; 2006 Dec 27; 12(12):1791-8. PubMed ID: 16823833 [Abstract] [Full Text] [Related]